Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split

What Happened Jupiter Neurosciences, Inc. (JUNS) filed an 8-K (Items 5.03 and 3.03) reporting a reverse stock split of its common stock at a ratio of 1-for-75. The company filed a Certificate of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, which becomes effective at 4:01 p.m. Eastern Time on August 6, 2026. Shares are expected to begin trading on a post‑split basis on The Nasdaq Capital Market at the open of trading on August 7, 2026 under the same ticker, JUNS. The company also issued a press release on August 5, 2026 announcing the action (filed as Exhibit 99.1).

Key Details

• Reverse Stock Split ratio: 1-for-75; every 75 pre-split shares will convert into 1 post-split share at the Effective Time (Aug 6, 2026, 4:01 p.m. ET).
• Trading: Post-split shares expected to begin trading on Nasdaq at market open on Aug 7, 2026; ticker remains "JUNS".
• Fractional shares: Stockholders entitled to fractional shares will receive a cash payment in lieu equal to the fractional share multiplied by the closing sales price on Nasdaq on the trading day immediately prior to the Effective Time, adjusted for the split.
• Other adjustments: Per-share exercise prices and numbers of shares issuable for outstanding options, warrants, convertibles and awards under stock incentive plans will be proportionately adjusted. Par value per share and the number of authorized shares are unchanged. New CUSIP after the split: 48208B302.

Why It Matters The Reverse Stock Split will consolidate the company’s issued and outstanding common shares (reducing share count by a 75-to-1 factor) and proportionally increase the per‑share figures. For holders, this means a direct conversion of shares (or cash in lieu for fractional shares), adjustments to option/warrant holdings and no change to total authorized shares. Trading will continue under the same ticker on Nasdaq beginning Aug 7, 2026; investors should note the new CUSIP and expect adjusted share balances and option/warrant terms after the Effective Time.